Status:
ACTIVE_NOT_RECRUITING
Tocilizumab Treatment in Patients With COVID-19
Lead Sponsor:
Instituto Nacional de Cancerologia de Mexico
Collaborating Sponsors:
Roche Pharma AG
Conditions:
Sars-CoV2
Eligibility:
All Genders
18-90 years
Phase:
PHASE2
Brief Summary
A phase II clinical trial will be carried out with the objective of studying the impact of the administration of Tocilizumab on the evolution of the acute respiratory distress syndrome (ARDS) in patie...
Detailed Description
In December 2019, a group of patients with the acute respiratory disease was detected in Wuhan, Hubei Province of China. A month later, a new beta-coronavirus was identified as the cause of the 2019 c...
Eligibility Criteria
Inclusion
- Patients 18 years or older
- Diagnosis of SARS-CoV-2 infection by RT-PCR
- Diagnosis of serious or critical illness, without mechanical ventilation or with less than 24 hours of mechanical ventilation.
- Severe: dyspnea, increase in respiratory rate ≥ 30 breaths / min, oxygen saturation \<90% or PaO2 \<60 mmHg or increase in supplemental oxygen requirement more than 3% from baseline, PaO2 / FiO2 \<300 mmHg, and / or pulmonary infiltrates by image\> 50% within 24 to 48 hours of symptom onset.
- Critical: respiratory failure (alteration in gas exchange with PaO2 \<60 mmHg with or without elevation of PaCO2\> 33 mmHg), septic shock (hypotension secondary to sepsis with a requirement for vasopressors to maintain a mean arterial pressure\> 65 mmHg and lactate\> 2 mmol / l).
- Signature of informed consent by the patient, family member or legal representative
- Negative pregnancy test for women of childbearing age.
- Male patients who agree to use barrier methods when having sexual intercourse in the following 80 days after receiving tocilizumab
- Patients receiving immunomodulatory treatment (cancer, transplant recipients or other diseases) that may temporarily suspend the drug.
Exclusion
- Pregnant or lactating women.
- Patients who by indication of their treating doctor cannot suspend previous immunomodulatory treatment.
- Known allergic reactions to Tocilizumab or any excipients.
- Patients receiving systemic steroids at a dose greater than 1 mg / Kg of weight per day in prednisone equivalents
- Patients with SOFA score\> 15 points that predicts 90% mortality on admission
- The decision of the attending physician not to include the patient due to the presence of any condition that does not allow the administration of the drug to be safe.
- Diverticulitis or intestinal perforation
- Patients with any of the following active infections: viral hepatitis, tuberculosis, HIV infection, bacterial and/or fungal and/or viral infections (other than SARS-CoV-2 infection) suspected or diagnosed using compatible microbiological isolation.
- Alanine aminotransferase/aspartate aminotransferase values\> 5 times the upper limit of normal
- Neutrophil values \<1000/ml,
- Platelet values \<50,000/ml.
Key Trial Info
Start Date :
June 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04363853
Start Date
June 1 2020
End Date
December 31 2025
Last Update
May 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Institute of Mexico
Mexico City, Mexico City, Mexico, 14080